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Background: Human brain microvascular endothelial cells (hBMVECs) are integral part of the blood brain barrier.
Post-translational modifications of adherens junction proteins regulate the permeability of human brain microvascular
endothelial cells. Pro-inflammatory signals can induce tyrosine phosphorylation of adherens junction proteins. The
primary objective of this work is to provide a molecular model; how the HIV-1 Tat protein can compromise the
BBB integrity and eventually lead to neurological consequences. We exposed hBMVECs to recombinant HIV-1 clade
C Tat protein to study the effect of HIV-1 Tat C on permeability of hBMVECs. Trans-endothelial electrical resistance
and fluorescent dye migration assay have been used to check the permeability of hBMVECs. DCFDA staining has been
used for intracellular reactive oxygen species (ROS) detection. Western blotting has been used to study the expression
levels and co-immunoprecipitation has been used to study the interactions among adherens junction proteins.
Results: HIV-1 Tat C protein induced NOX2 and NOX4 expression level and increased intracellular ROS level.
Redox-sensitive kinase; PYK2 activation led to increased tyrosine phosphorylation of VE-cadherin and β-catenin,
leading to disruption of junctional assembly. The dissociation of tyrosine phosphatases VE-PTP and SHP2 from cadherin
complex resulted into increased tyrosine phosphorylation of VE-cadherin and β-catenin in HIV-1 Tat C treated hBMVECs.
Conclusion: Unrestricted phosphorylation of junctional proteins in hBMVECs, in response to HIV-1 Tat C protein; leads
to the disruption of junctional complexes and increased endothelial permeability.
Keywords: HIV-1 Tat C, HIV Neuropathogenesis, ROS, Adherens junction proteins, NOX2, NOX4, Blood brain barrier,
Brain microvascular endothelial cellsBackground
HIV enters the central nervous system (CNS) by cross-
ing the blood brain barrier (BBB) during early stages of
HIV infection through infected blood cells [1,2]. HIV
infected cells secrete the Tat protein extracellularly [3]
and affect the functions of human brain microvascular
endothelial cells (hBMVECs) [4]. The hBMVECs form a
selective barrier between peripheral circulation and the
CNS. The barrier properties of hBMVECs are princi-
pally imparted by adherens junction proteins (AJPs) and
tight junction proteins (TJPs) [5]. VE-cadherin and* Correspondence: sunitsingh2000@gmail.com
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article, unless otherwise stated.catenin play major role in stabilization of adherens junc-
tions (AJs) and barrier integrity [6]. Cadherin complex is
composed of vascular endothelial-cadherin (VE-cadherin),
bound to β-catenin or plakoglobin, which in turn binds to
α-catenin; vinculin, α-actinin, ZO-1 and actin [7]. The
tyrosine phosphorylation of VE-cadherin complex is
critical for the integrity of the AJs and endothelial
permeability [8,9].
VE-PTP is a tyrosine phosphatase, transmembrane bind-
ing partner of VE-cadherin. It connects with VE-cadherin
through an extracellular domain and maintains the
unphosphorylated state of VE-cadherin [10]. Another
phosphatase; SHP2 is a ubiquitously expressed non-
receptor PTP, consisting of two N-terminal tandem
SH2 domains and a catalytic phosphatase (PTP) domain
and a C-terminal tail with two tyrosine residues [11].
Ukropec et al. [12]; reported SHP2 as a component ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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phorylation of both, β-catenin [12] and VE-cadherin [13].
Phosphorylated states of the VE-cadherin and β-catenin
regulate their interactions, and control the adhesion forces
[14]. VE-cadherin has many putative phospho-tyrosine
sites, but Y658, Y685, and Y731 phosphorylation are
reported to be important for maintaining the barrier
integrity [15]. PYK2 is a redox-sensitive tyrosine kinase
and gets activated by NADPH mediated ROS gener-
ation [16]. Tyrosine phosphorylation of β-catenin is
induced by PYK2 (proline rich kinase 2) [17] and de-
phosphorylated by SHP2 [18].
Pro-inflammatory factors affect the phosphorylated
state of VE-cadherin complex and disrupt the barrier
integrity [19,20]. In this study, we have selected HIV-1
Tat C to study the effect on endothelial permeability,
because HIV-1 clade C alone is responsible for more
than 56% of global HIV infections. HIV-1 clade C in-
fections are prevalent in South-east Asian countries
including India [21]. We have examined the effects of
the HIV-1 Tat C protein on redox-sensitive kinase
PYK2 and tyrosine phosphatases of VE-cadherin com-
plex (VE-PTP and SHP2) and their impact on tyrosine




Primary hBMVECs were obtained from Dr. Joan Berman,
department of pathology, Albert Einstein College of
Medicine, New York as a kind gift. hBMVECs were cul-
tured as described previously [22]. For all hBMVECs
cultures, the culture flasks were coated with 0.2% bovine
gelatin solution. CEM-GFP cells (NIH-AIDS Reagent
Programme) were used for transactivation assay to check
the biological activity of recombinant HIV-1 Tat C protein.
CEM-GFP cells were grown in RPMI 1640 (Gibco) sup-
plemented with 10% fetal bovine serum (Gibco), 2 mM
glutamine, 100 units of penicillin/streptomycin/ml. Cell
cultures were maintained at 37°C and constant supply
of 5% CO2 in a humidified incubator.
Expression and purification of HIV-1 Tat C protein
HIV-1 Tat C protein has been expressed and purified as
per our standardized protocol, described elsewhere in
detail [23]. Immunoconfirmation of recombinant HIV-1
Tat C protein was done by western blot analysis using
anti-Tat antibody (NIH AIDS Research and Reference
Reagent Program). Endotoxin level of purified recombin-
ant HIV-1 Tat C protein was measured by Limulus
Amebocyte Lysate (LAL) assay (Lonza) as per manufac-
turer’s protocol. The level of endotoxin was found in
range of 0.04 EU/μg of purified protein; which was much
below the acceptable limit set by international standards.Transcriptional activity of recombinant HIV-1 Tat C
protein was checked by transactivation assay as de-
scribed previously [23]. CEM-GFP cells are T-cell lines,
carrying a stably integrated GFP gene under the control
of HIV-1 subtype-B LTR. Purified HIV-1 Tat C protein
(5 μg) was transfected in CEM-GFP cells, with proteo-
juice protein transfection reagent (Novagen). GFP expres-
sions were visualized with fluorescence microscope (Axio
Observer-A1, Carl Zeiss, Germany). All protocols were
approved by the Centre for Cellular and Molecular Biology
(CCMB), Hyderabad Institutional Biosafety Committee.
HIV-1 Tat C treatment on human brain microvascular
endothelial cells
hBMVECs were grown as confluent monolayer and ex-
posed with HIV-1 Tat C protein at various doses
(100 ng/ml, 200 ng/ml, 500 ng/ml, and 1 μg/ml) in
serum-free M199 media. Control cells were treated
with Tat buffer (30 mM phosphate buffer, pH 6.8
supplemented with 1 mM DTT). BMVECs have been
exposed to Tat C at different concentration ranges due
to its closeness to reported serum levels and hBMVECs
would normally encounter such concentrations of Tat
in NeuroAIDS patients [3,24,25]. hBMVECs were har-
vested for RNA and protein sample preparation after
12 hours of HIV-1 Tat C protein treatments.
Western blot analysis
Cell lysis were done in RIPA buffer (150 mM NaCl,
50 mM Tris.HCL pH 7.5, 1% NP-40, 0.5% sodium doxy-
cholate, 0.1% SDS and 1× protease inhibitor cocktail).
Estimation of protein concentrations was done by Brad-
ford assay (Bio-Rad). Proteins samples were boiled in
SDS-loading buffer and run on 12% SDS-gel, transferred
on PVDF membrane (Millipore) at 100 V for 2 hrs.
Primary antibody incubations were given overnight at
4°C with dilutions (1:1000). HRP conjugated secondary
antibody were applied for 1 hour at room temperature
and developed by using Super Signal developing reagent
(Pierce, Thermo Scientific). Antibodies against p-Y-731-
VE-cadherin (Invitrogen), VE-cadherin, anti-β-tubulin,
NOX2 and NOX4 (Abcam), β-catenin (Santacruz bio-
technology), PYK2 (Cell signaling technology), SHP2
(Sigma) have been used in the study. VE-PTP antibody
was provided as a kind gift by Astrid F. Nottebaum,
Max Planck Institute of Molecular Medicine, Muenster,
Germany.
Transendothelial Electrical Resistance (TEER) Assay
EVOM2 (World precision Instruments) was used to meas-
ure electrical resistance across the endothelial monolayer.
PTFE membrane inserts (12 well plate) (Corning Life
sciences) consisting of 3.0 μm pore sizes were used in
the permeability assays. 0.2% bovine gelatin coating was
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adherence of hBMVECs. Cell seeding density was 2 × 104
in 500 μl of complete M199 media. To check the devel-
opment of junctional integrity, TEER values were
checked on regular intervals until reached at consistent
resistance in endothelial cells. After attaining the opti-
mal confluency, the hBMVECs were treated with differ-
ent doses of HIV-1 Tat C protein. TEER of hBMVECs
was measured after 12 hrs of HIV-1 Tat C protein ex-
posure. The resistance of empty insert membranes,
without cell seeding was deducted from recorded TEER
values.
Fluorescein migration assay
The fluorescein migration assay was performed as de-
scribed previously elsewhere [22]. hBMVECs were seeded
on membrane inserts in similar way as for TEER assay.
After treatment with different doses of Tat C proteins,Figure 1 HIV-1 Tat C mediated phosphorylation of adherens junction
check the effect of HIV-1 Tat C protein in hBMVECs, showing a dose depen
(B) The graph showing the result of densitometry for western blot images
VE-cadherin upon HIV-1 Tat/ heat inactivated Tat treatment. Quantitation o
β-tubulin. (C) Western blot analysis showing the insignificant effect of heat
of VE-cadherin (D) Western blot analysis to show dose dependent increase in
HIV-1 Tat C protein. (E) Densitometry analysis of image density to show chang
have been normalized with β-tubulin. All the experiments have been perf
as mean ± S.E., *above bars are representing the p value ≤0.05 as level ofcells were washed with HBSS buffer and incubated with
0.005% sodium fluorescein dye (SRL # 064738, mol
weight- 376.28) on upper chamber of the insert mem-
brane. hBMVECs were incubated with sodium fluores-
cein dye for 30 minutes at 37°C, followed by collection
of 100 μl of the flowthrough from lower chambers.
Fluorescence was measured at 480/530 nm wavelength
by using fluorimeter (Infinite M200, Tecon).
Co-immunoprecipitation of VE-cadherin/VE-PTP/β-catenin
and SHP2
Cells were pelleted after 12 hours of HIV-1 Tat C treat-
ment (500 ng/ml), washed with cold PBS and lysed in
NP-40 mild lysis buffer (NP-40 1%, Tris–HCl 50 mM,
NaCL 150 mM, NaF 1 mM, PMSF 2 mM, Sodium ortho-
vanadate 1 mM, Sodium pyrophosphate 10 mM, Protease
inhibiter cocktail 1×). Equal amounts of protein samples
were incubated with VE-cadherin antibody overnight atproteins (VE-cadherin and β-catenin). (A) Western blot analysis to
dent increase in tyrosine phosphorylation of VE-cadherin (p-Y-731).
showing significantly induced tyrosine phosphorylation (p-Y-731) of
f image densities have been done by ImageJ software normalized with
inactivated HIV-1 Tat C protein on tyrosine phosphorylation (p-Y-731)
tyrosine phosphorylation of β-catenin (p-Y-654) in hBMVECs exposed to
e in tyrosine phosphorylation (p-Y-654) of β-catenin. Image densities
ormed in three independent biological sets and results are presented
significance, n = 3. (*for p value ≤0.05, **for p value ≤0.005).
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sepharose beads for 3–4 hours followed by centrifugation.
The immunoprecipitated samples along with beads were
washed three times with lysis buffer and finally eluted by
boiling in SDS-loading buffer. The samples were run on
12/% SDS-Page gel and probed with respective antibodies.Intracellular Reactive Oxygen Species (ROS) detection by
Microscopy
hBMVECs were grown in 6 well culture dishes till con-
fluency. HIV-1 Tat treatment was given for 12 hours at the
different doses as described earlier. Cells were washed with
HBSS and treated with final concentration of 10 μM of cell
permeant fluorogenic dye 2’ 7’ dichlorofluorescein diacetate
(DCFDA) for 15 minutes at 37°C in incubator chamber.
After 15 minutes of incubation, cells were washed andFigure 2 Downregulation and dissociation of VE-PTP and SHP2 from
VE-PTP expression in HIV-1 Tat C treated hBMVECs. HIV-1 Tat C treatment h
done by using anti VE-PTP antibody to show decrease in expression level of p
of VE-PTP along with VE-cadherin complex showing the decreased associ
with VE-cadherin antibody to exhibit equal loading of pulled down cadhe
down of VE-cadherin complex by using NP-40 mild lysis buffer in cold con
C treated hBMVECs are showing a dose-dependent decrease in SHP2 exp
shown by immunoblotting against SHP2 in pulled down cadherin complex by
almost 60–70% decrease in VE-PTP expression at higher doses of HIV-1 Tat C tre
by VE-cadherin image density. Pull-down experiment has been repeated three t
of image density of SHP2 showing a significant dissociation (**p value ≤0.005) f
All the results shown here are representative of three independently repeated efluorescence was visualized under fluorescence microscope
(Axio Observer-A1, Carl Zeiss, and Germany).
Inhibition experiments
Chemical inhibiter against PYK2 (PF-431396) (Tocris
Bioscience) has been used to inhibit the kinase activity.
hBMVECs were cultured till confluency and treated with
22 nM PF-431396. Cells treated with equal volume of
DMSO have been taken as control. Diphenyleneiodo-
nium chloride (DPI) (Sigma Aldrich) dissolved in DMSO
has been used as ROS scavenger, at 100 nM concentra-
tion. hBMVECs were harvested for lysate preparation
after 12 hours of treatment.
Statistical analysis
Results have been expressed as the mean and standard
error of the mean. Level of significance in treated groupVE-cadherin in HIV-1 Tat C treated BMVECs. (A) Downregulation of
as been given for 12 hours on hBMVECs and western blot analysis was
hosphatase VE-PTP. (B) Immnunoblot images of co-immunoprecipitaion
ation of VE-PTP with VE-cadherin. Same blots have been re-probed
rin complex. Monoclonal VE-cadherin antibody has been used for pull
ditions. (C) Compared to control hBMVECs (buffer treated), HIV-1 Tat
ression levels. (D) SHP2 dissociation from cadherin complex has been
using anti VE-cadherin antibody. (E) The densitometry graph is showing
atment. (F) Quantitation of image density by ImageJ software normalized
imes and results are shown as mean ± S.E. (*p value ≤0.05). (G) Quantitation
rom cadherin complex, normalized with amount of VE-cadherin pull down.
xperiments and shown as mean ± S.E.
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dent’s t test. P-values < 0.05 have been taken as signifi-
cant in one tailed array.
Results
HIV-1 Tat mediated phosphorylation of adherens junction
protein (VE-cadherin and β-catenin)
We investigated the tyrosine phosphorylation of VE-
cadherin and β-catenin in hBMVECs treated with
increasing doses from 100 ng/ml to 1 μg/ml of HIV-1
Tat C. Both the adherens junction proteins (AJPs) (VE-
cadherin and β-catenin) were significantly phosphory-
lated up to 4 folds at their respective tyrosine positions
in dose dependent manner (Figure 1). We checked the
tyrosine phosphorylation (Y-731) of VE-cadherin in
hBMVECs exposed to heat inactivated Tat C and couldn’t
find any substantial alteration in VE-cadherin phos-
phorylation (Figure 1B, C).Figure 3 HIV-1 Tat C dissociates β-catenin from the VE-cadherin/β-cat
complex were pull down from control as well as HIV-1 Tat C treated hBMV
from VE-cadherin. (A) Coimmunoprecipetation of β-catenin with cadherin
significantly decreased association of β-catenin with VE-cadherin complex
of β-catenin with VE-cadherin in HIV-1 Tat C treated hBMVECs, shown by bar
repeated experiments. (C) The graph showing a dose dependent decrease in
hBMVECs as compared to buffer treated control cells. (D) Sodium fluorescein
flow through of fluorescent dye across the trans-well insert membrane, due to
Tat C protein.Downregulation and dissociation of VE-PTP and SHP2
from VE-cadherin complex in HIV-1 Tat treated human
BMVECs
VE-PTPs are essentially associated with VE-cadherin and
perform the function of keeping VE-cadherin in dephos-
phorylated state in quiescent cells [10]. We observed a
dose dependent increase in tyrosine phosphorylation of
VE-cadherin (Y731 position) in HIV-1 Tat C exposed
hBMVECs (Figure 1A, B). We further investigated the
levels of VE-PTP and their association with VE-cadherin
in HIV-1 Tat exposed hBMVECs. We observed decreased
expression of total VE-PTP (Figure 2A, E), along with
the significant dissociation (p ≤ .05) of VE-PTP from
VE-cadherin complex in HIV-1 Tat treated hBMVECs
(Figure 2B, F). SHP2, a non-receptor protein-tyrosine
phosphatase co-precipitates with VE-cadherin com-
plex in basal state of cells [12]. SHP2 phosphatase
maintains the integrity of VE-cadherin complex, byenin complex and induces endothelial permeability. VE-cadherin
ECs to examine the phosphorylation induced dissociation of β-catenin
complex, by using monoclonal anti VE-cadherin antibody, showing a
in HIV-1 Tat C treated hBMVECs. (B) A significant change in association
diagram. The bars are representing mean ± S.E. from three independently
TEER values across the trans-well insert membrane, in HIV-1 Tat C treated
dye migration assay, showing a dose dependent increase in amount of
increased permeability of hBMVECs exposed to increasing dose of HIV-1
Mishra and Singh BMC Neuroscience 2014, 15:80 Page 6 of 12
http://www.biomedcentral.com/1471-2202/15/80dephosphorylating VE-cadherin-associated β-catenin
as well as VE-Cadherin [13,18]. SHP2 expression levels
decreased significantly (p ≤0.005) along with increas-
ing dose of HIV-1 Tat (Figure 2C). The pull down
experiment with unit amount of VE-cadherin complex
by using monoclonal VE-cadherin antibody has shown
significant reduction (p ≤0.005) in SHP2 association
with VE-cadherin complex (Figure 2D, G). We ob-
served that both the tyrosine phosphatases regulating
the tyrosine phosphorylation, get dissociated from
the VE-cadherin complex in HIV-1 Tat C exposed
hBMVECs.
HIV-1 Tat dissociates β-catenin from the VE-cadherin/
β-catenin complex and induces endothelial permeability
HIV-1 Tat induced tyrosine phosphorylation of β-catenin
occurs in dose dependent manner (Figures 1D, E).
SHP2 and VE-PTP expression also got downregulated
and dissociated from VE-cadherin complex after HIV-
1 Tat treatment (500 ng/ml) in hBMVECs, leaving
VE-cadherin complex prone to the phopshorylation
(Figure 2). Co-immunoprecipitation of the cadherinFigure 4 HIV-1 Tat C upregulates NOX2 and NOX4 expression and inc
monitor the changes in expression levels of NOX2 and NOX4 in hBMVECs exp
proteins increased after HIV-1 Tat C treatment, and led to enhanced ROS prod
for western images for NOX2 and NOX4 normalized with image density of β-
and results are shown as mean ± S.E. The levels of significance in the changes
are indicated as *above the bar, (*for p value ≤0.05, **for p value ≤0.005). (D)
level in hBMVECs detected via DCFDA staining. Increasing doses of HIV-1
hBMVECs were treated with HIV-1 Tat C protein, washed with HBSS and inc
washed and visualized under microscope. Images were captured by Axio Obscomplex by monoclonal antibody of VE-cadherin sho-
wed 60% reduction (P ≤ 0.05) in the association of
β-catenin with VE-cadherin in HIV-1 Tat treated
hBMVECs (Figure 3A, B). Endothelial cell permeabil-
ity, assessed by TEER and sodium fluorescein migra-
tion assay showed an elevated permeability in HIV-1
Tat, treated hBMVECs (Figure 3C, D). Compared to
control cells, HIV-1 Tat treated hBMVECs, has shown
40–50% decrease in TEER values, however sodium
fluorescein migration assay has shown about 60–70%
increase in endothelial cell permeability in trans-well
membrane experiments (Figure 3C, D).
HIV-1 Tat upregulates NADPH oxidase (NOX2 and NOX4)
expression and increases ROS production in human
BMVECs
NADPH oxidases regulate ROS production; which
can affect the PTK (protein tyrosine kinase) and PTP
(protein tyrosine phosphates) balance in cells [26].
Intracellular ROS level can regulate PYK2 activation
and might play role in VE-PTP dissociation from cad-
herin complex [16]. We checked the expression levelreases ROS production in hBMVECs. (A) Western blot analysis to
osed to HIV-1 Tat C protein. The level of expression of both the NOX
uction by hBMVECs in a dose–dependent manner. (B, C) Densitometry
tubulin. The graphs are representative of three independent experiments
of the gene expression; compared to control groups, the p values ≤0.05
The figure showing fluorescence microscopic images of intracellular ROS
Tat C treatments are showing increase in ROS level in linear fashion.
ubated with DCFDA reagent (10 μM final concentration) for 15 minutes,
erver-A1 at 20 × magnification with GFP filters.
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production by DCFDA staining. We observed the
significant (p <0.005) induction in the expression
levels of NOX2 and NOX4 in HIV-1 Tat C exposed
hBMVECs (Figure 4A−C) and increase in the ROS
production in dose dependent manner (Figure 4D).
HIV-1 Tat activates PYK-2 in dose dependent manner
Proline-rich tyrosine kinase 2 (PYK2) is a non-receptor
tyrosine kinase, belongs to the focal adhesion kinase
(FAK) family [27]. HIV-1 Tat C exposed hBMVECs
showed a dose dependent increase in expression level of
NOX2 and NOX4 and levels of intracellular ROS. We
tested the level of phospho-PYK2 in HIV-1 Tat C
treated hBMVECs to delineate the role of PYK2 activa-
tion after Tat C treatment and to further find the role
of PYK2 activation in tyrosine phosphorylation of
β-catenin and VE-cadherin. A significant increase in the
levels of phospho-PYK2 (at Y-402) was observed in
hBMVECs (p ≤ .005) with increasing dose of HIV-1 Tat
C protein (Figure 5A, B). Application of 100nM DPI;
as ROS scavenger resulted into decreased PYK2 acti-
vation/phosphorylation (Figure 5C). ROS scavenging
helped in combating the effect of HIV-1 Tat C on
PYK2 activation (Figure 5C, D).Figure 5 HIV-1 Tat C activates PYK-2 in dose dependent manner. (A)
PYK2 as increased phosphorylated form of PYK2 at Y-402 position in HIV-1 Tat
(B) Densitometry of western blot images, done by ImageJ software to show q
HIV-1 Tat C treatment. Higher doses of HIV-1 Tat C protein significantly act
experiments and results are shown as mean ± S.E. (C) Western blot analysis fo
activation. (D) The graph bars are showing densitometry to show average cha
*to show the significance level of change between Tat C versus DPI + Tat C trROS scavenger (DPI) mediated rescue of SHP2 expression
and downregulation in phosphorylation of β-catenin
Redox-sensitive PYK2 activation and phosphorylation
of β-catenin leads to conformational disorganization of
cadherin complex in endothelial cells [28]. We exposed
hBMVECs with ROS scavenger DPI and studied the
effect of blocking ROS generation on PYK2 activation,
SHP2 expression, phosphorylation of β-catenin, and
endothelial permeability. We observed a sustained
expression level of SHP2 in DPI treated hBMVECs
(Figure 6A, B). Interestingly, DPI treatment helped in
rescuing of SHP2 expression even in Tat treated
hBMVECs (Figure 6A, B), which suggested the potential
of blocking the ROS on kinase/phosphatase balance in
hBMVECs. We checked the tyrosine phosphorylated
state of the β-catenin in DPI treated hBMVECs. DPI
treatment alone showed inhibition of the phosphoryl-
ation of β-catenin (Figure 6C, D) compared to highly
phosphorylated state (Y-654) of β-catenin in HIV-1
Tat exposed hBMVECs. DPI treatment followed by Tat
treatment resulted into decreased tyrosine phosphor-
ylation of β-catenin. Tat induced tyrosine phosphoryl-
ation of β-catenin mediated by ROS; resulted into
imbalance of kinases/phosphatases. The ROS scaven-
ging helped in ameliorating the effect of HIV-1 TatWestern blot images showing a dose dependent increase in activity of
C treated hBMVECs, as compared to control (buffer treated hBMVECs).
uantitative changes in phosphorylation of PYK2 at different doses of
ivated PYK2 (***shown for p value ≤0.0005) in three biological repeated
r phosphorylated PYK2 showing effect of ROS scavenger (DPI) on PYK2
nge in phosphorylated PYK2 after DPI treatment. P value ≤0.05 shown as
eated group.
Figure 6 ROS scavenger (DPI) mediated rescue of SHP2 expression and downregulation in phosphorylation of β-catenin. (A) Western
blot analysis for SHP2 expression level after DPI treatment and DPI treatment followed by HIV-1 Tat C treatment. DPI treatment shows significant
potential for checking the HIV-1 Tat C mediated downregulation of SHP2 expression. (B) The graph bars are showing average change in SHP2
expression normalized by β-tubulin. Image densitometry analysis has been done by ImageJ software. (C) Western blot analysis showing effect of
ROS inhibition on tyrosine phosphorylation of β-catenin. (D) The graph bars are representative of 3 independent experiments showing average
change in tyrosine phosphorylation of β-catenin in DPI treated hBMVECs. P-value ≤0.05 has been considered as significant and shown as *between
DPI + Tat C versus HIV-1 Tat C treated hBMVECs. (E) Change in TEER (Ώ/cm2) values after DPI treatment. The graph bars showing average change in
endothelial permeability after scavenging ROS by DPI. All the experiments have been performed three times independently and data shown as mean
± S.E. P value ≤0.0005 shown as ***asterisk to indicate the level of significance between Tat C treated versus DPI + Tat C treated hBMVECs.
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We observed that ROS inhibition by DPI treatment
has significantly helped in mitigating the effect of
HIV-1 Tat C protein on permeability of hBMVECs (p
≤0.005) (Figure 6E).
PYK2 inhibiter abrogates the phosphorylation of β-catenin
and rescues endothelial permeability
hBMVECs were treated with PYK2 inhibiter PF-431396
(Inhibiter of kinase activity) (Tocris Bioscience) and
checked for tyrosine phosphorylation of β-catenin.
Significant reduction in tyrosine phosphorylation of β-
catenin resulted into an accumulation of total β-catenin
(Figure 7A, B). No significant effect on tyrosine phos-
phorylation of β-catenin was observed in hBMVECs
treated with PYK2 inhibiter (PF-431396), followed by
HIV-1 Tat treatment. The level of total β-catenin wascomparable to PF-431396 treated hBMVECs (Figure 7A,
B). The effect of PF-431396 was also investigated on the
permeability of hBMVECs. The inhibition of PYK2 sig-
nificantly abrogated the effect of HIV-1 Tat and main-
tained the endothelial permeability (p ≤0.005) (Figure 7C).
Discussion
Neurological consequences still persist in the era of
HAART therapy, where viral load has been effectively
controlled in infected patients. However HIV-1 protein
such as Tat has been detected in the CSF of patients
kept on anti-retroviral therapy and show effectively con-
trolled viremia [29]. Therefore, we have focused on the
bystander effect of HIV-1 Tat protein on human brain
microvascular endothelial cells. In brain microvascular
endothelial cells, the levels of VE-cadherin regulate the
permeability of endothelial cells [9]. Vascular endothelial
Figure 7 PYK2 inhibiter abrogates the phosphorylation of β-catenin and rescues endothelial permeability. (A) Tyrosine phosphorylation
of β-catenin demonstrated after PYK2 inhibition by applying chemical inhibiter PF-431396. PYK2 inhibition significantly abrogated the tyrosine
phosphorylation of β-catenin even in HIV-1 Tat C exposed hBMVECs. Cells were treated with PF-431396 followed by treatment of HIV-1 Tat C protein
and treated cells were harvested after 12 hours for western blot analysis. (B) Densitometry analysis showing the significantly diminished tyrosine
phosphorylation of β-catenin in PF-431396 treated cells. All the experiments have been repeated as three independent biological sets and results
are shown as mean ± S.E. (*p value ≤0.05). (C) The graph bars are showing consequences of inhibiting PYK2 kinase activity on endothelial permeability.
PYK2 inhibiter provide significant rescuing of endothelial permeability as compared to HIV-1 Tat C treated human BMVECs (**p value ≤0.005). Results
are shown as mean ± S.E of three biological independent experiments.
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AJPs and TJPs [30]. We previously reported the post-
transcriptional regulation of VE-cadherin by miR-101 and
permeability in hBMVECs exposed to HIV-1 Tat C protein
[22]. Increased tyrosine phosphorylation of VE-cadherin
and associated catenins are known to compromises the
junctional architecture of endothelial cells, which dis-
rupts their physical interactions at cell-cell junctions
[8,19,20,31]. Inflammatory conditions change the mag-
nitude of tyrosine phosphorylation of AJPs [19,32-34].
Previously, phosphorylation of Y731 amino acid pos-
ition in VE-cadherin has been reported to be respon-
sible for impairing the association of VE-cadherin
with p120-catenin and β-catenin [15] during leukocyte
extravasation [35].
Different mechanisms and pathways have been re-
ported for the regulation of endothelial permeability.
Involvement of PPAR/lipid raft-dependent MMP-2 and
MMP-3 activation lead to the degradation of occludin
and tricellulin, which has been reported in C12-HSL-
induced perturbations of epithelial barrier functions[36]. Role of activation of ERK1/2 and Akt signaling
has been described for increased BBB permeability
through decreased tight junction (TJ) protein expres-
sions in brain microvascular endothelial cells. Tat me-
diated effects can be attenuated by application of PPAR
antagonist [37]. Another in vitro BBB model study
showed that HIV-1 infection of pericytes can also
result into compromised BBB integrity [38]. Another
recent study highlighted the role of Rho signaling and
CREB in triggering the nuclear localization of ZO-1
and perturbing the endothelial permeability after HIV-1
Tat exposure [39].
In our study, we observed a dose-dependent increase
in tyrosine phosphorylation of VE-cadherin at p-Y731
position and β-catenin at p-Y654 position (Figure 1A−E).
The Tyr-731 site is considered unique to VE-cadherin in
reference to endothelial permeability [15]. VE-cadherin
and β-catenin have shown induced phosphorylation at
their tyrosine positions accompanied by reduced expres-
sion of respective phosphatases VE-PTP and SHP2. Tyro-
sine phosphorylation of VE-cadherin and β-catenin which
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endothelial permeability and leakage [40].
We studied the role of kinases and phosphatases in
HIV-1 Tat induced tyrosine phosphorylation of AJPs.
We focused on PYK2 kinase because PYK2 is highly
redox sensitive kinase and its signaling gets affected by
intracellular ROS levels [26]. PYK2 has been described
as a critical regulator of endothelial inflammation via
phosphorylating IKK-RelA/p65 pathway, therefore fa-
cilitating the nuclear translocation of the RelA/p65
[41]. In our study, increased generation of ROS was ob-
served with the increasing doses of HIV-1 Tat C exposure
(Figure 4D). Role of NOX2 in HIV-1 Tat induced gener-
ation of ROS has been reported in human astrocytes,
where enhanced monocyte adhesion was regulated by
ROS mediated increase in ICAM/VCAM expression [42].
Secretion of TNF-α has also been reported to induce
NADPH oxidase-derived ROS generation and PYK2 acti-
vation in H9c2 cells [43]. In addition, PYK2-dependent
tyrosine phosphorylation has been reported to disrupt the
association of zonula occludens-2 with the endothelial
tight junctions [44]. Our study showed increased intracel-
lular ROS generation, followed by increase in phosphoryl-
ation and activation of PYK2, in HIV-1 Tat exposed
hBMVECs (Figure 5A, B). This explains the higher levels
of tyrosine phosphorylation in β-catenin and VE-cadherin
which will lead to increased endothelial cell permeability
(Figure 3C). As expected, ROS scavenging has significantlyFigure 8 HIV-1 Tat C mediated tyrosine phosphorylation of VE-cadhe
treatment induces the intracellular ROS generation by activating NADPH ox
of ROS activate the levels of redox sensitive kinase PYK2, which led to incre
C treatment also downregulates major phosphatases VE-PTP and SHP2 and
PTK/ PTP ratio in hBMVECs after HIV-1 Tat C exposure leads to destabilizedreduced the activation of PYK2 (Figure 5C, D) even in
presence of HIV-1 Tat in hBMVECs. PTPs act together
with cellular protein tyrosine kinases and control the
phosphorylation and dephosphorylation of substrate pro-
teins and associated signaling [45].
VE-PTP enhances VE-cadherin mediated cell–cell
adhesion and plays a major role in maintaining endothelial
barrier permeability [10]. The significant downregulation
of VE-PTP (p ≤0.05) (Figure 2A, E) and significant de-
crease in association of VE-PTP with VE-cadherin were
observed in HIV-1 Tat C exposed hBMVECs (Figure 2B, F).
In a recent report,Vockel et. al. (2013) reported the gen-
eration of ROS through activation of NADPH oxidases
and activation of redox-sensitive tyrosine kinase PYK2
and their effect on cell-cell junctions. They suggested
that activation of PYK2 could be essential for VE-
cadherin/VE-PTP dissociation [46]. In our study, the
downregulation and dissociation of VE-PTP from VE-
cadherin complex explains the high level of tyrosine
phosphorylation of VE-cadherin in HIV-1 Tat treated
hBMVECs. Another, non-receptor cytosolic tyrosine
phosphatase SHP2 has been reported to be associated
with β-catenin [12] and dephosphorylates β-catenin
and VE-cadherin in quiscent cells. We observed the
significant downregulation of SHP2 in HIV-1 Tat treated
hBMVECs in dose dependent manner (Figure 2C) and
a significant dissociation of SHP2 from VE-cadherin
complex.rin complex and increase in permeability of hBMVECs. HIV-1 Tat C
idases (NOX2/NOX4) proteins in hBMVECs. Elevated intracellular levels
ased tyrosine phosphorylation of β-catenin and VE-cadherin. HIV-1 Tat
leads to their dissociation from VE-cadherin complex. These shift in
junctional assembly and thereby enhanced endothelial permeability.
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cadherin and β-catenin [12]. We observed the separation
of β-catenin from VE-cadherin complex in pull down
experiment in HIV-1 Tat exposed hBMVECs (Figure 3A).
The disaggregation of VE-cadherin and β-catenin is
most likely due to the increased level of their tyrosine
phosphorylation. The disassembly of these proteins led
to the enhanced endothelial permeability in HIV-1 Tat
treated hBMVECs.
ROS generation activated the tyrosine kinases and ele-
vated phosphorylation of AJPs and finally disruption of
endothelial integrity. We scavenged the ROS by using
DPI followed by HIV-1 Tat treatment. ROS scavenging
significantly abolished the PYK2 activation (Figure 5C),
sustained SHP2 expression level (Figure 6A), and re-
duced tyrosine phosphorylation of β-catenin (Figure 6C)
in the hBMVECs. These changes resulted into improved
permeability in DPI treated hBMVECs (Figure 6E).
We checked the tyrosine phosphorylation of β-catenin
in hBMVECs treated with PYK2 inhibiter (PF-431396).
PF-431396 abrogates the kinase activity of PYK2/FAK
family kinases. A significant decrease in p-Y-β-catenin
was observed in the hBMVECs treated with PF-431396
(Figure 7A, B). Our data are in accordance with the
previous reports; where β-catenin has been reported to
act as a substrate of PYK2 kinase [17]. Phosphorylation
of β-catenin was also checked in the hBMVECs,
treated with PF-431396 followed by similar amount of
HIV-1 Tat protein exposure. The effect of HIV-1 Tat
on tyrosine phosphorylation of β-catenin was signifi-
cantly reduced in hBMVECs treated with PF-431396 as
well as in ROS scavenger treated hBMVECs, which
suggested that the β-catenin phosphorylation can be
controlled by manipulating PYK2 kinase activity and well
as intracellular ROS levels. Pharmacological inhibition of
PYK2 has been reported as a potential therapeutic strategy
to combat acute lung injury in patients as well as mice
model of asthma [41,47,48]. PYK2 inhibition rescued
the permeability of hBMVECs exposed to HIV-1 Tat
protein (Figure 7C). Inhibition of the PYK2 activity by
PF-431396 had a partial effect on tyrosine phosphoryl-
ation of VE-cadherin (data not shown). This suggested
that the phosphorylation events of VE-cadherin are also
partially regulated through Src and Rac mediated kinase
cascades [20].
Conclusion
HIV-1 Tat C mediated activation of NADPH oxidases
(NOX2/ NOX4) led to the increased generation of ROS
in hBMVECs and activation of PYK2 kinase. Upregula-
tion of PYK2 activity resulted into the increased tyrosine
phosphorylated forms of β-catenin and VE-cadherin.
The dissociation of VE-PTP and SHP2 from VE-cadherin
complex increased the tyrosine phosphorylation ofVE-cadherin/β-catenin, which led to disrupted physical
association of AJPs within VE-cadherin complex at
endothelial junctions. These conformational alter-
ations increased the permeability in hBMVECs. ROS
scavenging as well as inhibition of the PYK2 activity
showed a significant potential in combating the HIV-1
Tat C mediated disruption of endothelial permeability
(Figure 8). This study suggests the involvement of
post-translational modifications of AJPs in the disrup-
tion of barrier integrity in hBMVECs by HIV-1 Tat C
protein. This finding will be helpful in understanding
the effect of viral proteins in a bystander fashion on
human brain microvascular endothelial cells.
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